Payment overview · 2025
General Payments
$329.45
16 reported records · 8 companies
Healthcare provider profile · identity verified
Nicholas P Dardes, DO
Allopathic & Osteopathic Physicians|Internal Medicine · BEAUFORT, SC · NPI 1083723688
Verified facts
What the public records show
CMS Open Payments records show Nicholas P Dardes, DO received $329.45 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.19 | 24.6% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $73.97 | 22.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.70 | 11.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.00 | 9.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.31 | 9.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.77 | 7.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.58 | 7.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.93 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.45 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.19 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $73.97 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.80 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.00 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.00 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $31.31 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 121 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
121 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 923 | 263 |
| Levothyroxine Sodium | Levothyroxine Sodium | 602 | 124 |
| Metformin Hcl | Metformin Hcl | 589 | 165 |
| Losartan Potassium | Losartan Potassium | 571 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 156 |
| Gabapentin | Gabapentin | 384 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 374 | 129 |
| Furosemide | Furosemide | 347 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 89 |
| Omeprazole | Omeprazole | 297 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 91 |
| Lisinopril | Lisinopril | 271 | 91 |
| Simvastatin | Simvastatin | 263 | 69 |
| Eliquis | Apixaban | 239 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 65 |
| Famotidine | Famotidine | 216 | 47 |
| Carvedilol | Carvedilol | 209 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 46 |
| Methylprednisolone | Methylprednisolone | 186 | 155 |
| Lorazepam | Lorazepam | 169 | 38 |
| Alprazolam | Alprazolam | 159 | 49 |
| Allopurinol | Allopurinol | 156 | 46 |
| Ozempic | Semaglutide | 152 | 35 |
| Montelukast Sodium | Montelukast Sodium | 148 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 42 |
| Prednisone | Prednisone | 129 | 74 |
| Spironolactone | Spironolactone | 123 | 32 |
| Mounjaro | Tirzepatide | 121 | 19 |
| Trazodone Hcl | Trazodone Hcl | 120 | 37 |
| Glipizide | Glipizide | 118 | 34 |
| Ezetimibe | Ezetimibe | 113 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 49 |
| Atenolol | Atenolol | 112 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 32 |
| Potassium Chloride | Potassium Chloride | 102 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 29 |
| Cefdinir | Cefdinir | 92 | 74 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 73 |
| Memantine Hcl | Memantine Hcl | 88 | 12 |
| Nifedipine Er | Nifedipine | 88 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 27 |
| Valsartan | Valsartan | 85 | 25 |
| Azithromycin | Azithromycin | 78 | 69 |
| Synthroid | Levothyroxine Sodium | 75 | 17 |
| Levetiracetam | Levetiracetam | 74 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 14 |
| Meloxicam | Meloxicam | 72 | 26 |
| Finasteride | Finasteride | 69 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 20 |
| Levofloxacin | Levofloxacin | 68 | 54 |
| Pregabalin | Pregabalin | 66 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 49 |
| Jardiance | Empagliflozin | 63 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 14 |
| Tramadol Hcl | Tramadol Hcl | 59 | 17 |
| Buspirone Hcl | Buspirone Hcl | 58 | 15 |
| Megestrol Acetate | Megestrol Acetate | 58 | 18 |
| Cephalexin | Cephalexin | 57 | 50 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 14 |
| Dutasteride | Dutasteride | 55 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 16 |
| Sertraline Hcl | Sertraline Hcl | 55 | 14 |
| Celecoxib | Celecoxib | 53 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Donepezil Hcl | Donepezil Hcl | 51 | 13 |
| Temazepam | Temazepam | 51 | 17 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 11 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 35 |
| Azelastine Hcl | Azelastine Hcl | 43 | 28 |
| Chlorthalidone | Chlorthalidone | 43 | 12 |
| Ketoconazole | Ketoconazole | 43 | 27 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 13 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 42 | suppressed |
| Bumetanide | Bumetanide | 40 | suppressed |
| Clonazepam | Clonazepam | 40 | 11 |
| Latanoprost | Latanoprost | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 17 |
| Ibuprofen | Ibuprofen | 34 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 30 |
| Meclizine Hcl | Meclizine Hcl | 31 | 15 |
| Digoxin | Digoxin | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Diazepam | Diazepam | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 23 |
| Olanzapine | Olanzapine | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 17 |
| Baclofen | Baclofen | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 13 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 16 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Misoprostol | Misoprostol | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Glyburide | Glyburide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.45 · 16 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, KRYSTEXXA, Korlym, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error